R&D channel feed

Gene edit­ing for heart dis­ease: Verve kicks off land­mark base edit­ing tri­al

3 years ago
Cell/Gene Tx

Pli­ant claims ear­ly win for in­te­grin in­hibitor in chal­leng­ing IPF space — shares soar

3 years ago

Io­n­is hands off an an­ti­sense drug for kid­ney dis­ease, giv­ing all rights to Roche

3 years ago
Deals

Two years af­ter scrap­ping three he­mo­phil­ia tri­als, No­vo Nordisk plots route to FDA with new PhI­II da­ta

3 years ago

In wake of un­ex­pect­ed pa­tient deaths, Macro­Gen­ics clos­es down PhII can­cer tri­al

3 years ago

Sanofi’s next-gen he­mo­phil­ia drugs take a PhI­II bow — but can they still make their mark at this stage?

3 years ago

A year af­ter with­draw­ing IPO, Dy­nacure scraps lead drug for rare mus­cle dis­eases

3 years ago

Ad­verum lays off 38% of staff as it en­ters new tri­al for oc­u­lar gene ther­a­py af­ter last year's safe­ty woes

3 years ago
People
Cell/Gene Tx

Leg­end scraps tri­al of its fol­low-up au­tol­o­gous CAR-T weeks af­ter clin­i­cal hold was lift­ed

3 years ago
China
Cell/Gene Tx

Two years af­ter CRL, In­ter­cept will meet with FDA lat­er this month to dis­cuss new analy­sis of NASH drug

3 years ago

As ALS pa­tients unite around Amy­lyx, a new pa­per hints at po­ten­tial drug­gable tar­gets

3 years ago
AI
Discovery

Low-pro­file biotech led by Bris­tol My­ers vets grabs a suite of adeno­sine re­cep­tor an­tag­o­nists via tiny buy­out

3 years ago

Cy­tomX halts lead pro­gram and will seek a part­ner as breast can­cer drug dis­ap­points

3 years ago

Heart in­flam­ma­tion emerges in a Sarep­ta Duchenne pa­tient, cloud­ing an oth­er­wise pos­i­tive read­out

3 years ago
Cell/Gene Tx

Ap­plied Mol­e­c­u­lar Trans­port’s shot at beat­ing Hu­mi­ra in UC fails in mid-stage study, sink­ing shares near­ly 30%

3 years ago

Re­org com­ing for lit­tle biotech as it shut­ters PhII ra­dioim­munother­a­py tri­al on un­der­whelm­ing da­ta

3 years ago

Texas drug man­u­fac­tur­er smacked with FDA warn­ing let­ter over mul­ti­ple vi­o­la­tions

3 years ago
Manufacturing

FDA lifts hold on Ver­tex's di­a­betes stem cell ther­a­py af­ter just two months un­der the mi­cro­scope

3 years ago
Cell/Gene Tx
FDA+

An­oth­er Duchenne clin­i­cal hold gets lift­ed, this time at Dyne Ther­a­peu­tics

3 years ago
FDA+

In a twist, Amy­lyx's ALS drug will get a sec­ond crack at ad­comm en­dorse­ment af­ter FDA de­cides to re­con­vene ex­perts

3 years ago
FDA+

Seagen touts full PhII Tukysa da­ta as it plots col­orec­tal can­cer ex­pan­sion

3 years ago
Pharma

En­do adds to a pile­up of bad news as lead drug flunks PhII study

3 years ago

Bay­er's re­search and de­vel­op­ment teams set­tle in­to new, $140M Kendall Square digs

3 years ago
Pharma

Tak­ing aim at Xo­lair, Celldex of­fers a pos­i­tive ear­ly read­out for their ri­val drug — but re­searchers have a lot of work re­main­ing

3 years ago
First page Previous page 128129130131132133134 Next page Last page
A service from the Financial Times